Riskpilot← Back to searchSign inGet full accessApoLipo AB
ABDissolvedOrg 5590337969Research and experimental development on biotechnology · NACE 7211Est. 20150 employees
Revenue 2021
SEK 125K
+363% vs 2020
EBITDA margin
-7.2%
-325% vs 2020
Equity ratio
100.0%
Financial strength
Net profit 2021
SEK 0
-100% vs 2020
| Revenue | SEK 125K | +363% |
| EBITDA | SEK -9K | -325% |
| Net profit | SEK 0 | -100% |
| Total assets | SEK 51K | -83% |
| Equity | SEK 51K | +0% |
| Employees | 0 | — |
Legal name
ApoLipo AB
Org number
5590337969
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
5 november 2015
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Company purpose
Bolaget ska utveckla, sälja och marknadsföra metoder och reagenser för studier av och diagnostik kring plasmaproteiner och andra proteiner med speciell inriktning på proteiner involverade i transport och bearbetning av blodfetter. Bolaget ska verka som konsulter inom nämnda områden, äga och förvalta fast och lös egendom inklusive aktier och andra värdepapper samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 27 | 125 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | −1 101 | −1 | −1 | −1 | 4 | −9 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −4 | −0 |
| EBIT | −1 101 | −1 | −1 | −1 | 0 | −9 |
| Net financials | — | — | — | — | — | — |
| Profit before tax | 0 | −1 | −1 | −1 | 4 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −1 | −1 | −1 | 4 | 0 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Total assets | 1 150 | 1 148 | 1 147 | 47 | 302 | 51 |
| Equity | 50 | 49 | 48 | 47 | 51 | 51 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 100 | 1 099 | 1 099 | 0 | 251 | 0 |
| Total debt | 1 100 | 1 099 | 1 099 | — | 251 | — |
EBITDA margin
-7.2%
This company
15.8%
Market median
-146% vs market
20162021
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20162021
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20162021
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20162021
Asset turnover
2.45×
This company
1.12×
Market median
+119% vs market
20162021
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20162021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-11-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SB Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ApoLipo AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sten Braesch-Andersen | Chief Executive Officer | 0 companies |
| Staffan Paulie | Board of Directors | 0 companies |
| Oscar Olov Östrand | Chairman | 0 companies |
| Carl Olov Östrand | Board of Directors | 0 companies |
| Kjell Olov Östrand | Chairman | 0 companies |